EcoDrugPlus

Endothelial Pas Domain Protein 1b

Ensembl ID : ENSMAMG00000002532
Gene Symbol: EPAS1B
2 Cross references
210 Possible Orthologues:

Endothelin Converting Enzyme 1

Ensembl ID : ENSMAMG00000002669
Gene Symbol: ECE1
3 Cross references
230 Possible Orthologues:

Endothelin Receptor Ba

Ensembl ID : ENSMAMG00000017721
Gene Symbol: EDNRBA
2 Cross references
195 Possible Orthologues:

Endothelin Receptor Type A

Ensembl ID : ENSMAMG00000006802
Gene Symbol: EDNRA
3 Cross references
197 Possible Orthologues:

Endothelin Receptor Type Aa

Ensembl ID : ENSMAMG00000013980
Gene Symbol: EDNRAA
3 Cross references
205 Possible Orthologues:

Endothelin Receptor Type B-Like

Ensembl ID : ENSMAMG00000013038
Gene Symbol: LOC113123396
2 Cross references
196 Possible Orthologues:

Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit

Ensembl ID : ENSMAMG00000008409
Gene Symbol: EZH2
2 Cross references
229 Possible Orthologues:

Eph Receptor B4b

Ensembl ID : ENSMAMG00000011060
Gene Symbol: EPHB4B
2 Cross references
168 Possible Orthologues:

Epidermal Growth Factor Receptor A (Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog, Avian)

Ensembl ID : ENSMAMG00000017162
Gene Symbol: EGFRA
3 Cross references
212 Possible Orthologues:

Equilibrative Nucleoside Transporter 1-Like

Ensembl ID : ENSMAMG00000021698
Gene Symbol: LOC113131715
2 Cross references
209 Possible Orthologues:

Equilibrative Nucleoside Transporter 1-Like

Ensembl ID : ENSMAMG00000016866
Gene Symbol: LOC113140146
2 Cross references
210 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 2

Ensembl ID : ENSMAMG00000013531
Gene Symbol: ERBB2
3 Cross references
200 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).